Top 5 most read articles on liver disease in 2021


Chronic liver disease is on the increase, and the burden is expected to increase in the future, both in the United States and globally. These are the most read articles on liver disease in 2021.

Non-alcoholic fatty liver disease (NAFLD) is a largely asymptomatic silent disease and its incidence is increasing. About 37% of American adults and up to 70% of people with type 2 diabetes have NAFLD. Non-alcoholic steatohepatitis (NASH) is a subtype of NAFLD and is characterized by inflammation and swelling; if left untreated, it can lead to liver fibrosis, cirrhosis and hepatocellular cancer (HCC).

This is a collection of our most widely read liver disease articles exploring this complex topic in 2021.

5. Approach the management of NAFLD with a multidisciplinary clinic model

The complexity of NALFD, coupled with metabolic diseases, heart and diabetic complications, and lifestyle factors, makes it ideal for a multidisciplinary model of care, according to a study published in Hepatology. Multidisciplinary care can help prevent progression, which is essential as NAFLD becomes more prevalent, the researchers noted. reviewed current models of multidisciplinary care teams and introduced a framework for building a comprehensive NAFLD program at Weill Cornell Medicine in New York.

Read the entire article.

4. Tremelimumab added to Durvalumab shows positive results in HCC

The results presented in October showed the first positive results of the phase 3 HIMALAYA trial according to which the addition of biological tremelimumab to durvalumab demonstrated a statistically and clinically significant overall survival benefit compared to sorafenib as the first treatment. line for patients with unresectable HCC. The combination demonstrated a favorable safety profile and the addition of tremelimumab to durvalumab did not increase severe hepatic toxicity. The patients had not received previous systemic treatment and were not eligible for spot treatment.

Read the entire article.

3. A poorly differentiated tumor size linked to a poorer prognosis in HCC, according to a study

Tumor size is an important prognostic indicator of survival in HCC, and the researchers said their findings can help providers tailor treatment strategies. Published in the journal Liver cancer in August, the study examined whether the prognostic effect of tumor differentiation on survival outcomes is altered by tumor size. Poorly differentiated HCC appears disorganized and tends to spread aggressively; the researchers said a key finding is that tumors ≥ 5 cm in size have a 2.33 times greater risk of early extrahepatic recurrence.

Read the entire article.

2. Coffee consumption associated with less stiffness of the liver

Coffee is associated with less stiffness of the liver, but not steatosis, and may be beneficial for people with or at risk for liver disease, according to a study published in Clinical gastroenterology and hepatology in October. The results came from a sample of individuals from the National Health and Nutrition Examination Survey; the greatest benefit was seen in those who drank more than 3 cups per day.

Read the entire article.

1. Launch of the clinical care pathway for NAFLD and NASH

This fall, a new clinical care pathway was released for health care providers including primary care, endocrinologists, obesity medicine specialists, and gastroenterologists to use when managing patients with the disease. of NAFLD and NASH. The journey describes a 4-step screening process to identify patients earlier to prevent disease progression and encourage value-based care. The tracking also stratifies patients according to low and high risk.

Read the entire article.


Comments are closed.